Peroxisome proliferator-activated receptor-γ is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth

Marilee Wick, Greg Hurteau, Christina Dessev, Daniel Chan, Mark W. Geraci, Robert A. Winn, Lynn E. Heasley, Raphael A. Nemenoff

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the growth of different cancer cell types, suggesting a broad role for their cyclooxygenase (COX) targets and eicosanoid products in tumor cell growth. Sulindac sulfide, a COX inhibitor, inhibited the growth of non-small-cell lung cancers (NSCLC) both in soft agar and as xenografts in nude mice. Importantly, the concentration of sulindac sulfide required to inhibit NSCLC cell growth greatly exceeded the concentration required to inhibit prostaglandin (PG) E2 synthesis in NSCLC cells, suggesting that NSAID inhibition of cell growth is mediated by additional targets distinct from COX. Both sulindac sulfide and ciglitazone, a defined peroxisome proliferator-activated receptor-γ (PPARγ) agonist, stimulated a promoter construct containing a PPAR response element linked to luciferase and potently inhibited NSCLC cell growth at similar concentrations, indicating a role for PPARγ as a target of NSAID action in these cells. Overexpression of PPARγ in NSCLC cells strongly inhibited the transformed growth properties of the cells, providing a molecular confirmation of the results obtained with the PPARγ agonists. Increased expression of PPARγ, as well as ciglitazone and sulindac sulfide induced expression of E-cadherin, which has been linked to increased differentiation of NSCLC. Despite the fact that SCLC cell lines expressed little or no cytosolic phospholipase A2, COX-1, or COX-2, sulindac sulfide and PPARγ agonists also inhibited the transformed growth of these lung cancer cells. We propose that PPARγ serves as a target for NSAIDs that accounts for COX-independent inhibition of lung cancer cell growth.

Original languageEnglish (US)
Pages (from-to)1207-1214
Number of pages8
JournalMolecular Pharmacology
Volume62
Issue number5
DOIs
StatePublished - Nov 1 2002
Externally publishedYes

Fingerprint

Peroxisome Proliferator-Activated Receptors
Prostaglandin-Endoperoxide Synthases
Lung Neoplasms
Anti-Inflammatory Agents
Non-Small Cell Lung Carcinoma
Growth
Pharmaceutical Preparations
Cytosolic Phospholipases A2
Cyclooxygenase 1
Cyclooxygenase Inhibitors
Eicosanoids
Response Elements
Cadherins
Cyclooxygenase 2
Luciferases
Dinoprostone
Heterografts
Nude Mice
Agar
Neoplasms

ASJC Scopus subject areas

  • Pharmacology

Cite this

Peroxisome proliferator-activated receptor-γ is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. / Wick, Marilee; Hurteau, Greg; Dessev, Christina; Chan, Daniel; Geraci, Mark W.; Winn, Robert A.; Heasley, Lynn E.; Nemenoff, Raphael A.

In: Molecular Pharmacology, Vol. 62, No. 5, 01.11.2002, p. 1207-1214.

Research output: Contribution to journalArticle

Wick, Marilee ; Hurteau, Greg ; Dessev, Christina ; Chan, Daniel ; Geraci, Mark W. ; Winn, Robert A. ; Heasley, Lynn E. ; Nemenoff, Raphael A. / Peroxisome proliferator-activated receptor-γ is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth. In: Molecular Pharmacology. 2002 ; Vol. 62, No. 5. pp. 1207-1214.
@article{693dc45414a94e598317ab611366eebe,
title = "Peroxisome proliferator-activated receptor-γ is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth",
abstract = "Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the growth of different cancer cell types, suggesting a broad role for their cyclooxygenase (COX) targets and eicosanoid products in tumor cell growth. Sulindac sulfide, a COX inhibitor, inhibited the growth of non-small-cell lung cancers (NSCLC) both in soft agar and as xenografts in nude mice. Importantly, the concentration of sulindac sulfide required to inhibit NSCLC cell growth greatly exceeded the concentration required to inhibit prostaglandin (PG) E2 synthesis in NSCLC cells, suggesting that NSAID inhibition of cell growth is mediated by additional targets distinct from COX. Both sulindac sulfide and ciglitazone, a defined peroxisome proliferator-activated receptor-γ (PPARγ) agonist, stimulated a promoter construct containing a PPAR response element linked to luciferase and potently inhibited NSCLC cell growth at similar concentrations, indicating a role for PPARγ as a target of NSAID action in these cells. Overexpression of PPARγ in NSCLC cells strongly inhibited the transformed growth properties of the cells, providing a molecular confirmation of the results obtained with the PPARγ agonists. Increased expression of PPARγ, as well as ciglitazone and sulindac sulfide induced expression of E-cadherin, which has been linked to increased differentiation of NSCLC. Despite the fact that SCLC cell lines expressed little or no cytosolic phospholipase A2, COX-1, or COX-2, sulindac sulfide and PPARγ agonists also inhibited the transformed growth of these lung cancer cells. We propose that PPARγ serves as a target for NSAIDs that accounts for COX-independent inhibition of lung cancer cell growth.",
author = "Marilee Wick and Greg Hurteau and Christina Dessev and Daniel Chan and Geraci, {Mark W.} and Winn, {Robert A.} and Heasley, {Lynn E.} and Nemenoff, {Raphael A.}",
year = "2002",
month = "11",
day = "1",
doi = "10.1124/mol.62.5.1207",
language = "English (US)",
volume = "62",
pages = "1207--1214",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "5",

}

TY - JOUR

T1 - Peroxisome proliferator-activated receptor-γ is a target of nonsteroidal anti-inflammatory drugs mediating cyclooxygenase-independent inhibition of lung cancer cell growth

AU - Wick, Marilee

AU - Hurteau, Greg

AU - Dessev, Christina

AU - Chan, Daniel

AU - Geraci, Mark W.

AU - Winn, Robert A.

AU - Heasley, Lynn E.

AU - Nemenoff, Raphael A.

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the growth of different cancer cell types, suggesting a broad role for their cyclooxygenase (COX) targets and eicosanoid products in tumor cell growth. Sulindac sulfide, a COX inhibitor, inhibited the growth of non-small-cell lung cancers (NSCLC) both in soft agar and as xenografts in nude mice. Importantly, the concentration of sulindac sulfide required to inhibit NSCLC cell growth greatly exceeded the concentration required to inhibit prostaglandin (PG) E2 synthesis in NSCLC cells, suggesting that NSAID inhibition of cell growth is mediated by additional targets distinct from COX. Both sulindac sulfide and ciglitazone, a defined peroxisome proliferator-activated receptor-γ (PPARγ) agonist, stimulated a promoter construct containing a PPAR response element linked to luciferase and potently inhibited NSCLC cell growth at similar concentrations, indicating a role for PPARγ as a target of NSAID action in these cells. Overexpression of PPARγ in NSCLC cells strongly inhibited the transformed growth properties of the cells, providing a molecular confirmation of the results obtained with the PPARγ agonists. Increased expression of PPARγ, as well as ciglitazone and sulindac sulfide induced expression of E-cadherin, which has been linked to increased differentiation of NSCLC. Despite the fact that SCLC cell lines expressed little or no cytosolic phospholipase A2, COX-1, or COX-2, sulindac sulfide and PPARγ agonists also inhibited the transformed growth of these lung cancer cells. We propose that PPARγ serves as a target for NSAIDs that accounts for COX-independent inhibition of lung cancer cell growth.

AB - Nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit the growth of different cancer cell types, suggesting a broad role for their cyclooxygenase (COX) targets and eicosanoid products in tumor cell growth. Sulindac sulfide, a COX inhibitor, inhibited the growth of non-small-cell lung cancers (NSCLC) both in soft agar and as xenografts in nude mice. Importantly, the concentration of sulindac sulfide required to inhibit NSCLC cell growth greatly exceeded the concentration required to inhibit prostaglandin (PG) E2 synthesis in NSCLC cells, suggesting that NSAID inhibition of cell growth is mediated by additional targets distinct from COX. Both sulindac sulfide and ciglitazone, a defined peroxisome proliferator-activated receptor-γ (PPARγ) agonist, stimulated a promoter construct containing a PPAR response element linked to luciferase and potently inhibited NSCLC cell growth at similar concentrations, indicating a role for PPARγ as a target of NSAID action in these cells. Overexpression of PPARγ in NSCLC cells strongly inhibited the transformed growth properties of the cells, providing a molecular confirmation of the results obtained with the PPARγ agonists. Increased expression of PPARγ, as well as ciglitazone and sulindac sulfide induced expression of E-cadherin, which has been linked to increased differentiation of NSCLC. Despite the fact that SCLC cell lines expressed little or no cytosolic phospholipase A2, COX-1, or COX-2, sulindac sulfide and PPARγ agonists also inhibited the transformed growth of these lung cancer cells. We propose that PPARγ serves as a target for NSAIDs that accounts for COX-independent inhibition of lung cancer cell growth.

UR - http://www.scopus.com/inward/record.url?scp=0036839817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036839817&partnerID=8YFLogxK

U2 - 10.1124/mol.62.5.1207

DO - 10.1124/mol.62.5.1207

M3 - Article

C2 - 12391285

AN - SCOPUS:0036839817

VL - 62

SP - 1207

EP - 1214

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 5

ER -